Imatinib Mesylate and Gemcitabine in Treating Patients With Locally Advanced, Metastatic, or Recurrent Pancreatic Cancer
Pancreatic Cancer
About this trial
This is an interventional treatment trial for Pancreatic Cancer focused on measuring recurrent pancreatic cancer, stage III pancreatic cancer, stage IV pancreatic cancer
Eligibility Criteria
DISEASE CHARACTERISTICS: Histologically confirmed pancreatic cancer Locally advanced, metastatic, or recurrent disease Measurable or evaluable disease by physical exam, plain radiographs, CT scan, or MRI No brain metastases PATIENT CHARACTERISTICS: ECOG performance status 0-2 Life expectancy of 12 weeks or greater Absolute neutrophil count ≥ 1,500/mm^3 Platelet count ≥ 100,000/mm^3 Bilirubin ≤ 1.5 times upper limit of normal (ULN) AST ≤ 2.5 times ULN (5 times ULN if liver metastases are present) No chronic liver disease (i.e., chronic active hepatitis or cirrhosis) Creatinine ≤ 2.0 mg/dL No chronic renal disease Not pregnant or nursing Negative pregnancy test Fertile patients must use effective barrier-method contraception during and for ≥ 3 months after completion of study treatment No other malignancy within the past 5 years except basal cell skin cancer or carcinoma in situ of the cervix No uncontrolled diabetes No active uncontrolled infection No other severe and/or uncontrolled medical disease HIV negative PRIOR CONCURRENT THERAPY: No prior therapy for metastatic disease Prior fluorouracil as a radiosensitizer for adjuvant therapy after surgery or for locally advanced disease is permitted if local disease has recurred or progressed ≥ 3 months after completion of therapy or disease is present outside the radiation field At least 2 weeks since prior major surgery No concurrent grapefruit or grapefruit juice
Sites / Locations
- Robert H. Lurie Comprehensive Cancer Center at Northwestern University